Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F18%3A43913470" target="_blank" >RIV/00216208:11120/18:43913470 - isvavai.cz</a>

Alternative codes found

RIV/00064173:_____/18:N0000156

Result on the web

<a href="https://doi.org/10.1080/10428194.2017.1357175" target="_blank" >https://doi.org/10.1080/10428194.2017.1357175</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/10428194.2017.1357175" target="_blank" >10.1080/10428194.2017.1357175</a>

Result language

angličtina

Original language name

Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma

Original language description

Temsirolimus 175 mg once-weekly for 3 weeks, followed by 75 mg once-weekly intravenously dosed (175/75 mg) is approved in the European Union for treatment of relapsed/refractory mantle cell lymphoma (MCL). A phase IV study explored whether similar efficacy, but improved safety could be achieved with 75 mg without 175 mg loading doses (ClinicaTrials.gov: NCT01180049). Patients with relapsed/refractory MCL were randomized to once-weekly temsirolimus 175/75 mg (n = 47) or 75 mg (n = 42). Treatment continued until objective disease progression. Primary endpoint: progression-free survival (PFS). Secondary endpoints included overall survival (OS) and adverse events (AEs). Median PFS was 4.3 versus 4.5 months (hazard ratio [HR] 0.731; 80% confidence interval [CI], 0.520-1.027), and median OS 18.7 versus 11.0 months (HR 0.681; 80% CI, 0.472-0.982) with 175/75 mg versus 75 mg. There were fewer patients with serious AEs, dose reduction, or death with 175/75 mg (57.4%, 48.9%, and 48.9%) versus 75 mg (73.8%, 64.3%, and 65.1%). Temsirolimus 175/75 mg remains the preferred dosing regimen for relapsed/refractory MCL.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Leukemia &amp; Lymphoma

ISSN

1042-8194

e-ISSN

—

Volume of the periodical

59

Issue of the periodical within the volume

3

Country of publishing house

GB - UNITED KINGDOM

Number of pages

9

Pages from-to

670-678

UT code for WoS article

000423431600017

EID of the result in the Scopus database

2-s2.0-85026854198